

Special Issue

Morphomolecular Characterization of Neoplastic and Pre-neoplastic Lesions in Solid Malignancies

Message from the Guest Editors

Traditionally, morphological evaluation represented the conventional approach for diagnosing and classifying neoplastic and pre-neoplastic lesions. However, recent advancements in molecular biology techniques have deeply revolutionized our understanding of solid malignancies contributing to the investigation of genetic alterations, gene expression patterns, epigenetic modifications, and protein expression that drive tumor initiation, progression, and metastasis. This knowledge has opened up opportunities for the development of targeted therapies that specifically inhibit these pathways. Moreover, molecular profiling integrated with morphological analysis can significantly improve diagnostic accuracy, prognostic stratification, and tailored treatment strategies, leading to improved therapeutic outcomes and minimizing adverse effects. We especially welcome original translational research studies highlighting new findings in the abovementioned areas, and short communications of preliminary but significant experimental results. In addition, experts in the field will review the current diagnostic, therapeutic, and experimental models.

Guest Editors

Dr. Giuseppe Nicolò Fanelli

Dr. Edoardo Francini

Dr. Pier Vitale Nuzzo

Dr. Cristian Scatena

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/176136

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).